Virtual Reality Therapy for Schizophrenia Symptoms
Effect of Virtual Reality-based Therapy on Negative Symptoms in People with Schizophrenia
Recruiting
N/AInterventional Study
Schizophrenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 65
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
102 (estimated)
Sponsor
Hospital de la Florida Dra. Eloiza Diaz · Other
Who this trial is looking for
This trial is looking for individuals diagnosed with schizophrenia to test a new virtual reality therapy. Participants will receive therapy sessions for 12 weeks while continuing their usual treatment.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with schizophrenia.
I am between 18 and 65 years old.
I am living as an outpatient.
I have not been hospitalized for mental health issues in the last 6 months.
I do not have an active substance abuse disorder, except for nicotine.
I can give informed consent.
You may not be able to join if
I have a learning disability.
I have trouble speaking due to health issues.
I am deaf or blind.
I have physical issues that prevent me from using VR devices.
I have significant positive symptoms of schizophrenia.
I have catatonic symptoms.
I have been diagnosed with epilepsy.
I have a neurodegenerative disease.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
A randomised, controlled, double-blind clinical trial will be carried out to evaluate the effectiveness of a VR assisted treatment for negative symptoms in people with schizophrenia. Patients with a standardised diagnosis of schizophrenia meeting the inclusion criteria will receive 12 weekly sessions of VR assisted therapy plus treatment as usual (TAU). A control group will be exposed to a neutral…
A randomised, controlled, double-blind clinical trial will be carried out to evaluate the effectiveness of a VR assisted treatment for negative symptoms in people with schizophrenia. Patients with a standardised diagnosis of schizophrenia meeting the inclusion criteria will receive 12 weekly sessions of VR assisted therapy plus treatment as usual (TAU). A control group will be exposed to a neutral VR environment plus TAU. The hypothesis is that patients who are treated with active VR assisted therapy will have less negative symptoms as rated by the PANSS-N scale, compared to the control group.
The protocol was approved by the hospital ethics committee of the Servicio de Salud Metropolitano Suroriente. Patients sign an informed consent form, from which they may withdraw at any point during the intervention.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of schizophrenia made by the treating psychiatrist and corroborated by a team's psychiatrist under CIE-10 criteria.
* Age between 18 to 65 years-old.
* Outpatient setting,
* Clinical stability defined as no psychiatric hospitalizations in the last 6 months and not cu…
Inclusion Criteria:
* Diagnosis of schizophrenia made by the treating psychiatrist and corroborated by a team's psychiatrist under CIE-10 criteria.
* Age between 18 to 65 years-old.
* Outpatient setting,
* Clinical stability defined as no psychiatric hospitalizations in the last 6 months and not currently on queue for psychiatric hospitalization.
* No concomitant active substance abuse disorder, excluding nicotine.
* Subjects are capable of providing informed consent.
Exclusion Criteria:
* Previous diagnosis of learning disability according either to ICD- 10 or clinical history
* Verbal expression difficulties, determined by language or medical causes.
* Deafness and/or blindness.
* Other physical handicaps to use VR devices.
* Predominant positive symptoms, defined as PANNS-C \> 0.
* Catatonic symptoms.
* Previous epilepsy diagnosis.
* Neurodegenerative disease.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.